Document is current
Any future updates will be listed below
-
Authors
Chandak, Swati https://orcid.org/0000-0001-8255-6253
Gurudas, Sarega
Pakeer, Raheeba Mohammed
Kazantzis, Dimitrios https://orcid.org/0000-0002-4145-8144
Ghanchi, Faruque https://orcid.org/0000-0002-4448-8162
Grabowska, Anna https://orcid.org/0000-0002-3053-2142
Talks, Stephen James
Pearce, Ian
McKibbin, Martin https://orcid.org/0000-0003-4388-243X
Kotagiri, Ajay
Menon, Geeta
Burton, Benjamin JL https://orcid.org/0000-0001-9579-9078
Gale, Richard
Sivaprasad, Sobha
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim (SIVS1045)
- License Information
-
More Information
Article History
Received: 8 November 2024
Revised: 8 January 2025
Accepted: 5 February 2025
First Online: 21 February 2025
Competing interests
: Sivaprasad reported receiving financial support from AbbVie, Alimera Science, Amgen, Apellis, Astellas, Bayer, Biogen, Boehringer Ingelheim, Clearside Biomedical, Eyebiotech, Eyepoint Phamaceuticals, Iveric Bio, Janssen Pharmaceuticals, Nova Nordisk, Optos, Ocular Therapeutix, Kriya Therapeutics, OcuTerra, Ripple Therapeutics, Roche, Stealth Biotherapeutics and Sanofi. Sobha Sivaprasad is the Editor-in-Chief of EYE. Faruque Ghanchi has received honorarium for consultancy-advisory boards from Alimera, Allergan, Bayer, Novartis, Oxford BioElectronics, Roche; educational travel grants from Allergan, Bayer, Novartis. James Talks is a consultant for Bayer and Roche, received grant support from Bayer, Roche, and Heidelberg Engineering, and is involved in research for, Roche, Bayer, Janssen Pharmaceutical,s and Boehringer-Ingelheim. Ian Pearce - IP has received lecture fees from Allergan, Bayer, Heidelberg, and Novartis, consultancy fees from Allergan, Alimera, Bayer, and Novartis and travel fees from Allergan, Bayer, and Novartis; Martin McKibbin has received lecture and advisory board honoraria from Bayer and Novartis and an educational travel grant from Bayer; Ajay Kotagiri received travel support from Novartis, Bayer, and Allergan, and speaker fees from Allergan and Bayer; Geeta Menon has conducted consultancy-advisory boards for Novartis, Bayer and Allergan, received educational travel grants from Novartis, Bayer, Allergan; Benjamin Burton is in the advisory board and received international conference attendance sponsored by Novartis and Bayer; Richard Gale has conducted consultancy-advisory boards for Novartis, Bayer and Allergan, Alimera, Santen, received educational travel grants from Novartis, Bayer, Allergan, Heidelberg Engineering. The remaining author declares no competing interests.
